Cantargia Q4 2024: Focus on Business Development - Redeye

Redeye comments on Cantargia's Q4 report. The company faces a major catalyst in the first placebo-controlled readout of nadunolimab towards mid-year. The MAD results from CAN10, including in psoriasis patients, during this year will also be an important catalyst. Positive results can position Cantargia for a deal with either candidate. We think Cantargia needs to partner with at least one of them.

Länk till analysen i sin helhet: https://www.redeye.se/research/1082134/cantargia-q4-2024-focus-on-business-development?utm_source=finwire&utm_medium=RSS